Abstract:Oseltamivir is an ethyl ester prodrug of Ro 64-0802, a selective inhibitor of influenza virus neuraminidase. Oral administration of oseltamivir delivers the active antiviral Ro 64-0802 to the bloodstream, and thus all sites of influenza infection (lung, nasal mucosa, middle ear) are accessible.The pharmacokinetic profile of oseltamivir is simple and predictable, and twice daily treatment results in effective antiviral plasma concentrations over the entire administration interval. After oral administration, oseltamivir is readily absorbed from the gastrointestinal tract and extensively converted to the active metabolite. The absolute bioavailability of the active metabolite from orally administered oseltamivir is 80%. The active metabolite is detectable in plasma within 30 minutes and reaches maximal concentrations after 3 to 4 hours. After peak plasma concentrations are attained, the concentration of the active metabolite declines with an apparent half-life of 6 to 10 hours.Oseltamivir is eliminated primarily by conversion to and renal excretion of the active metabolite. Renal clearance of both compounds exceeds glomerular filtration rate, indicating that renal tubular secretion contributes to their elimination via the anionic pathway. Neither compound interacts with cytochrome P450 mixed-function oxidases or glucuronosyltransferases.The pharmacokinetic profile of the active metabolite is linear and dose-proportional, with less than 2-fold accumulation over a dosage range of oseltamivir 50 to 500mg twice daily. Steady-state plasma concentrations are achieved within 3 days of twice daily administration, and at a dosage of 75mg twice daily the steady-state plasma trough concentrations of active metabolite remain above the minimum inhibitory concentration for all influenza strains tested.Exposure to the active metabolite at steady state is approximately 25% higher in elderly compared with young individuals; however, no dosage adjustment is necessary. In patients with renal impairment, metabolite clearance decreases linearly with creatinine clearance. A dosage reduction to 75mg once daily is recommended for patients with creatinine clearance <30 ml/min (1.8 L/h). The pharmacokinetics in patients with influenza are qualitatively similar to those in healthy young adults.In vitro and in vivo studies indicate no clinically significant drug interactions. Neither paracetamol (acetaminophen) nor cimetidine altered the pharmacokinetics of Ro 64-0802. Coadministration of probenecid resulted in a 2.5-fold increase in exposure to Ro 64-0802; however, this competition is unlikely to result in clinically relevant effects.These properties make oseltamivir a suitable candidate for use in the prevention and treatment of influenza.

Anti-Influenza Prodrug Oseltamivir is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation is Inhibited by Antiplatelet Agent Clopidogrel

Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802

The Drug Interactions Study of Clopidogrel in vitro

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms

Oseltamivir: a clinical and pharmacological perspective

Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.

Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling

Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein

Surge in Expression of Carboxylesterase 1 During the Post-Neonatal Stage Enables a Rapid Gain of the Capacity to Activate the Anti-Influenza Prodrug Oseltamivir.

In Vitro Interaction of Clopidogrel and Its Hydrolysate with OCT1, OCT2 and OAT1.

Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors

Aspirin Attenuates The Bioactivation Of And Platelet Response To Vicagrel In Mice

Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol.

Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS.

[Impact of Proton Pump Inhibitor Omeprazole on the Antiplatelet Effect of Clopidogrel in Individuals with Various CYP2C19*2 Genotypes].

Enhanced Platelet Response to Clopidogrel in Zucker Diabetic Fatty Rats Due to Impaired Clopidogrel Inactivation by Carboxylesterase 1 and Increased Exposure to Active Metabolite

Divalent Oseltamivir Analogues As Potent Influenza Neuraminidase Inhibitors.

Pharmacokinetic/Pharmacodynamic Assessment of the Structural Refinement of Clopidogrel Focusing on the Balance Between Bioactivation and Deactivation

Simultaneous analyses of hemodynamic and electrophysiological effects of oseltamivir along with its pharmacokinetic profile using the canine paroxysmal atrial fibrillation model

Oseltamivir Inhibits Both Viral Entry and Release but Enhances Apoptosis of Cells Infected with Influenza A H1N1

The hydrophobic side chain of oseltamivir influences type A subtype selectivity of Neuraminidase inhibitors.